TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03589547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~\*3 fractions are allowed for centrally located tumors
Study: NCT01498328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rindopepimut (CDX-110) with GM-CSF
Description: Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rindopepimut (CDX-110) with GM-CSF
Description: Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH
Description: KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
Study: NCT05770583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation
Description: * FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~* FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98~* FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SpO2 (oxygen saturation)
Description: Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
Study: NCT00785018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-esterase inhibitor
Description: C1-esterase inhibitor 100 U/kg infusion over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin administration
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin administration
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
Study: NCT02134197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupartumab Amadotin (BAY1129980)
Description: Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
Study: NCT03161132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated Liposomal Doxorubicin
Description: PLD 40mg/m2 every 28 days intravenous
Study: NCT01880216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin sodium
Description: subcutaneous application daily for 7±2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: subcutaneous for 7±2 days
Study: NCT04068610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.
Study: NCT01675219

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: white light TUR-BT
Description: traditional transurethral bladder tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blue light TUR-BT
Description: photodynamic transurethral bladder tumor resection
Study: NCT04068610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
Study: NCT00656643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Two subconjunctival injections of 440 micrograms sirolimus each.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subconjunctival injections of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Two subconjunctival injections of 220 micrograms sirolimus each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Two subconjunctival injections of 880 micrograms sirolimus each.
Study: NCT04068610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive IV infusion of bevacizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive IV infusion of bevacizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive IV infusion of bevacizumab as stated in arm description.
Study: NCT00600535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 Group 1: abiraterone acetate
Description: 1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 Group 1: abiraterone acetate
Description: 1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 Group 2: abiraterone acetate
Description: 1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 Group 2: abiraterone acetate
Description: 1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2: abiraterone acetate
Description: 1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2: abiraterone acetate
Description: 1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 3: abiraterone acetate
Description: 1000 mg tablets/day orally for 12 cycles (28 days/cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 3: glucocorticoid
Description: prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 4: abiraterone acetate
Description: 1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 4: glucocorticoid
Description: prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
Study: NCT03170856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-maximal exercise
Description: Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
Study: NCT04520373

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Management: Occupational and Physical Therapy
Description: Observation while undergoing Occupational and Physical Therapy for 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, Adipose Derived Mesenchymal Stem Cells
Description: The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous, Adipose Derived Mesenchymal Stem Cells
Description: The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
Study: NCT01588249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized maple syrup

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03374631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active anodal tDCS
Description: active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: active anodal tDCS
Description: active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
Study: NCT00514566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture for midline abdominal closure
Description: closure with Polyamide or Polydioxanone
Study: NCT03512899

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right internal jugular access.
Description: Implantation using percutaneous puncture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left internal jugular access.
Description: Implantation using percutaneous puncture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right axillary vein access.
Description: Implantation using percutaneous puncture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left axillary vein access.
Description: Implantation using percutaneous puncture.
Study: NCT01902433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Astym

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Astym
Study: NCT01634763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Study: NCT02370277

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of stool samples

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of stool samples

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of stool samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01067976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
Study: NCT00589290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat (PDX101)
Description: 1000 mg/m\^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
Study: NCT04502979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive Feeding Training
Description: Families will receive 4 monthly 1-hour sessions: (1) Signing with infants; (2) infant communication and responsive feeding; (3) nutrition, portion sizes, and neophobia; and, (4) infant intentionality.
Study: NCT02549729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
Study: NCT00932737

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-5 tablets per episode
Study: NCT06679725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild ginseng extract
Description: This ginseng extract was manufactured and provided by the Korea Food Research Institute (sponsor). It is extracted from red ginseng. Red ginseng is generally considered to have greater biological effects and fewer side effects than white or fresh ginseng.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% Korean wild Ginseng Extract. This was achieved by incor-porating 0.25% scented ginseng and 0.06% caramel coloring
Study: NCT04127292

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Emotional Self Awareness (ESA) Individual Feedback
Description: Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Self Awareness (ESA) Individual Feedback
Description: Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
Study: NCT01643434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone (titrating dose from 12.5 to 50mg SID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Clonidine (titrating dose from 0.100-0.300mg BID)
Study: NCT01647997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bacterial endotoxin challenge
Description: iv administration of 2ng/kg bacterial endotoxin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bacterial endotoxin challenge
Description: iv administration of 2ng/kg bacterial endotoxin
Study: NCT02482558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High/Low Glycaemic index test breakfast
Description: High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
Study: NCT00932737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBB 20 mg
Description: Active drug, one to five tablets per episode
Study: NCT03312998

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Xrays
Description: Plain x-rays anteroposterior and lateral views to determine system failure
Study: NCT03296735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ipsilateral tilt
Description: The operation table will be tilted 20 degrees right laterally.
Study: NCT01027351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.
Description: Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.
Description: Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.
Description: Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.
Description: Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)
Description: Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)
Description: Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
Study: NCT02757963

Intervention type: OTHER
Group type: OTHER
Intervention: Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool
Description: The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score \>=3) and meet all other eligibility requirements will be enrolled in Part I of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: International Prostate Symptom Score (IPSS) screening tool
Description: The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score \>=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
Study: NCT03696693

Intervention type: DEVICE
Intervention: acoustic vocal analysis
Description: Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)

Intervention type: DEVICE
Intervention: acoustic vocal analysis
Description: Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
Study: NCT02958501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colecalciferol
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colecalciferol
Description: Drug
Study: NCT04126551

Intervention type: OTHER
Intervention: Methylation status
Description: Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function

Intervention type: OTHER
Intervention: Methylation status
Description: Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function

Intervention type: OTHER
Intervention: Methylation status
Description: Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
Study: NCT01433731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for SHAPE (SHP-141)
Description: topical gelled solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE (SHP-141) 0.1% BID
Description: topical gelled solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE (SHP-141) 0.5% BID
Description: topical gelled solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE (SHP-141) 1.0% BID
Description: topical gelled solution
Study: NCT02600429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4